BioSpace News Archive

Business

RaySearch Laboratories : Interim report January 1 - June 30, 2023

Yonsei Cancer Center, South Korea, treated its first patient using RayStation and RayCare for carbon ion radiation therapy.

August 25, 2023
·
2 min read
Drug Development

Zhiyi Biotech Announced First Subject Dosed in the U.S. Phase 1 clinical Trial of SK10, in Development for Treatment of Chemotherapy-induced Diarrhea

Zhiyi Biotech announced that the first three subjects have been dosed in the U.S. Phase 1 clinical trial of SK10, an innovative heat-killed Bacteroides fragilis product developed by Zhiyi Biotech for Chemotherapy-induced Diarrhea.

August 25, 2023
·
2 min read
Novocure to Participate in Upcoming September 2023 Investor Conferences

Novocure announced that management will participate in two upcoming investor conferences.

August 25, 2023
·
3 min read
Business

IIOT-OXYS, Inc. Reports 2023 Form 10-Q Second Quarter Results and Upcoming Investor Conference Call

IIOT-OXYS, Inc. (OTC PINK:ITOX) (“Oxys” or the “Company”) announced its financial results for the six months ended June 30, 2023, and an upcoming Investor Conference Call on Tuesday, August 29, 2023.

August 25, 2023
·
6 min read
Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study in Long QT Syndrome. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT induced by Dofetilide

Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in individuals with dofetilide-induced long QT.

August 25, 2023
·
5 min read
BioMidwest

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 25, 2023

Assertio Holdings, Inc. announced that effective August 21, 2023, the Compensation Committee of the Company’s Board of Directors granted one newly-hired employee a total of 11,585 restricted stock units and 12,745 stock options.

August 25, 2023
·
3 min read
Business

Biomerica Reports Fiscal 2023 Year End Results

Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2023 financial results.

August 25, 2023
·
8 min read
Genetown

Myomo Announces Pricing of $4.4 Million Public Offering

Myomo, Inc. announced the pricing of its “reasonable best efforts” public offering of 7,333,334 shares of common stock at a public offering price of $0.60 per share for aggregate gross proceeds of approximately $4.4 million, before deducting placement agent fees and other offering expenses.

August 25, 2023
·
5 min read
Drug Development

Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746.

August 25, 2023
·
2 min read
Business

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), today announced its interim results for the six-months ended June 30, 2023, and provided updates on multiple milestones achieved since the beginning of 2023.

August 25, 2023
·
10 min read